You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest General Articles
Popular General Articles
Highly Recommended General Articles
Send a link to this page to your friends and colleagues.
SmithKline Beecham, maker of the glitazone Avandia, is working with doctors to help the transition of patients taking Rezulin to safer alternatives. SmithKline Beecham will be offering special services for type 2 diabetes patients to get more information about glitazones.
"Avandia is a clear choice for patients who need to transition from Rezulin to another glitazone, which will allow them to continue therapy with a safer and effective treatment alternative," said David Krause, MD., vice president and director of clinical research development and medical affairs at SmithKline Beecham.
Over 700,000 patients have started taking Avandia in the United States and more than two million prescriptions have been written. It is approved for the treatment of type 2 diabetes in more than 26 countries.
Liver tests are recommended in all patients prior to initiation of therapy with Avandia and periodically thereafter. Avandia was generally well tolerated in clinical trials. Commonly reported adverse events were upper respiratory tract infections and headaches.
For more information, log on to SmithKline Beecham's Web site at www.sb.com.
0 comments - May 1, 2000
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.